Dear Drugs-Forum readers: We are a small non-profit that runs one of the most read drug information & addiction help websites in the world. We serve over 3 million readers per month, and have costs like all popular websites: servers, hosting, licenses and software. To protect our independence we do not run ads. We take no government funds. We run on donations which average $25. If everyone reading this would donate $5 then this fund raiser would be done in an hour. If Drugs-Forum is useful to you, take one minute to keep it online another year by donating whatever you can today. Donations are currently not sufficient to pay our bills and keep the site up. Your help is most welcome. Thank you.
A thread for experiences with Methoxypiperamide will be created if and when it is necessary.
_____________________________________ Other names: MEXP IUPAC name: (4-methoxyphenyl)(4-methylpiperazin-1-yl)methanone
1-(4-methoxybenzoyl)-4-methylpiperazine CAS number: 55154-30-8 (freebase), 41804-96-0 (hydrochloride salt) Chemical formula: C13H18N2O2 Molecular mass: 234.29g/mol
Not much available info on this one, just started popping up on a few vendor sites, with vague descriptions of similarities with BZP deduced by 'in-vitro' experiments and wild speculations of its mechanism of action
No idea of the dosage or effects as of yet, nor if it is even active orally
As to legality in the UK the The Misuse of Drugs Act 1971 (Amendment) Order 2009 states that
1–benzylpiperazine or any compound structurally derived from 1–benzylpiperazine or 1–phenylpiperazine by modification in any of the following ways—
(i) by substitution at the second nitrogen atom of the piperazine ring with alkyl, benzyl, haloalkyl or phenyl groups;
(ii) by substitution in the aromatic ring to any extent with alkyl, alkoxy, alkylenedioxy, halide or haloalkyl groups.”;
Now the above compound falls foul of both of those definitions, having a methoxy moiety on the aromatic ring and being methylated at the nitrogen, however, does that ketone somehow cause it it slip past this law? Possibly, instead of being a methoxyphenyl group it could be classed as methoxybenzoyl
To anyone who is willing to try a BZP analogue, good luck, stay safe and start way low. It may look like BZP but may well be active at much lower doses
Anyone who tried pFPP will know that that had a very trippy edge to it, made you just want to stare at stuff and not particularly socialise. And that was active at low doses, 20mg - 50mg was more than enough. Best to start very carefully indeed. My Aunties gorilla was discussing aquiring some as he really liked BZP, but at the moment doesn't really have enough bananas to trade for a research chem that could be not all it's hyped up to be.
Ugh, can anyone else make a casual assumption that this is going to be as awful as the rest of the piperazines? Regardless of what analog it may be, they usually turn out to be a dirty stimulant experience at best. Just more stuff that ends up cutting good MDMA as it would be...
There are so many readily available cathinone stimulants which are still legal in a lot of countries. It would seem that someone is just doing this to give it a try. I thought these things disappeared before 2010. I guess there are more things to worry about now.
I wonder if this one has the same detrimental health effects that BZP had. Apparently it was found as toxic to the kidneys and liver after the years of "Fake MDMA" abusers took it for too long.
I am going to throw this article in here so people can relate back. Sometimes these analogues can be worse for you, so I feel it is pertinent for harm reduction sake:
Scientists at Anglia Ruskin University haves shown that one of the most common 'legal high' designer drugs, benzylpiperazine, is not only dangerous when it's taken - repeated consumption poses major health risks.
The rate at which new designer drugs are being synthesised is increasing rapidly
According to study leader Mike Cole, BZP users claim it has similar effects to ecstasy, but without some of the more unpleasant side-effects. 'It was reclassified as a controlled drug in the UK in December 2009,' he says. 'Before this, it was made by people who did it for a living, and it was relatively pure. The legislation drove the synthesis underground, as it's a fairly straightforward one-pot reaction, but once the drug is made it starts to react with the starting materials, and badly made BZP also contains other substances such as dibenzylpiperazine.'
Cole's group, in conjunction with his colleague Lata Gautam, made a number of batches of BZP under different conditions to manipulate the proportions of the impurities. They then tested them against several human cell lines - fibroblasts, liver and kidney cells - both singly and as mixtures. They found that BZP is toxic to the kidney, while the precursor piperazine is toxic to the liver. The impurities are even more harmful and have synergistic effects with BZP itself. 'The damage you see is greater than the sum of the parts,' he says. 'If people suspected to have taken these drugs end up in hospital, medics should do liver and kidney function tests, as it's not always immediately apparent that damage has occurred,' he says.
The research was presented at the annual meeting of the American Academy of Forensic Sciences.
According to Ric Treble, scientific advisor at LGC, the number of these 'legal high' drugs is increasing rapidly. 'I believe 41 new compounds were identified last year,' he says. 'They are often sold as "research chemicals" and there is very little information about their short or long term effects.
Rogue chemists study the chemical literature in search of the next big 'high', Treble says, and make a lot of money out of them. 'They are mostly small chemicals that are relatively easy to make. The belief is they were initially being made in custom labs in China, where they have access to the chemicals and expertise to make them very quickly. The BZPs were, perhaps, the first examples of these, and governments are now rushing to try and control new ones as they appear.'
According to David Nichols, professor of pharmacology at Purdue University, people make and try new ones, and then post information about them on blogs.
'Benzylpiperazines are not that difficult to make, and you could make thousands of them with different substitutions,' he says. 'I doubt we've yet touched the surface of what's likely to be active, and what will appear on the market next. No doubt people are going to start making some of these to see if they can hit on one that's really marketable.'
The next step for Cole's group is to understand better how the cells deal with the drugs. 'We want to understand which metabolic processes are switched on and off to cause the damage, and how this can be used to help patients,' he says. 'We also want to raise awareness of just how dangerous these drugs are.'